We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
CNS drug developer Newron grosses CHF118mm in IPO on SWX
18 Dec 2006
Executive Summary
Italian firm Newron Pharmaceuticals SPA (CNS diseases) has raised CHF118mm ($99mm) through its initial public offering on the SWX Swiss Exchange. It sold 2.15mm shares for CHF55 each, landing in the upper end of its planned CHF45-60 price range.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
IPO
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?